Representing Lupin in trade secret misappropriation action against TranspireBio.
Representing Eli Lilly in patent litigation against multiple generics involving Lilly’s Reyvow® (lasmiditan hemisuccinate) for the treatment of migraines.
Representing Finch and the University of Minnesota in patent litigation brought by Ferring and Rebiotix concerning gut microbiome products. After a five-day jury trial, the jury returned a verdict of willful infringement and no invalidity, and awarded Finch and UMN over $25 million in damages.
Represented Eli Lilly at the ITC against several importers of falsely marked and/or advertised tirzepatide products (Certain Products Containing Tirzepatide and Products Purporting to Contain Tirzepatide, 337-TA-1377), the active ingredient in Lilly’s Mounjaro® and Zepbound®. The Commission issued a general exclusion order preventing importation of products containing or purporting to contain tirzepatide that infringe Lilly’s Mounjaro® trademark and/or are falsely designated in a way that suggests the product is associated with Lilly or has received FDA approval.
Represented Bristol-Myers Squibb in numerous Hatch-Waxman patent infringement litigations regarding cancer therapy Sprycel® (dasatinib). Sprycel® is a cancer drug used to treat patients with chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Cases settled during fact and expert discovery.
Represented Eagle Pharmaceuticals in patent litigation brought by Par Pharma companies involving Eagle’s ANDA for the generic version of Par's Vasostrict® (vasopressin injection) for the treatment of hypotension/low blood pressure in patients experiencing vasodilatory shock. After a bench trial, the Court found that Eagle’s ANDA product did not infringe Par’s asserted patents. The Federal Circuit affirmed the district court’s judgment of noninfringement in a precedential opinion.
Represented Teva in patent litigation brought by Janssen involving Teva’s ANDA for the generic version of Invega Sustenna® (paliperidone palmitate) for the treatment of schizophrenia and schizoaffective disorder.
Represented Teva in patent litigation brought by Celgene involving Teva’s ANDA for the generic version of Celgene’s Pomalyst® (pomalidomide). Teva obtained favorable settlement during expert discovery after years of litigation.
Represented biosimilar drug maker in all phases of patent dance proceedings under the BPCIA and early stages of litigation.
Represented Samsung Electronics in patent litigation brought by Greenthread concerning semiconductor devices. Case settled during expert discovery.
